Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.
Rheumatoid arthritis (RA) is a chronic inflammatory disease that frequently affects people aged >or=65 years, causing significant impairment with pain and functional disability. Elderly RA patients have specific problems, including co-morbid diseases, numerous concomitant medications, greater number of damaged joints as a result of longer disease duration and often a more severe disease presentation in elderly-onset RA. These factors, together with an age-related decline in the immune defence mechanisms, make elderly patients more vulnerable. The new era of biologic medications has made intensive treatment of RA patients possible. Anti-tumour necrosis factor-alpha (anti-TNFalpha) agents can cause a dramatic improvement in disease activity and functional capacity, making complete remission of RA a possible target. TNFalpha has been shown to play an important role in both the healthy aging process and age-related diseases such as RA. Targeting this cytokine in elderly patients is therefore reasonable. However, it is not clear whether treatment effects can be reached to the same extent in both elderly and younger patients and whether anti-TNFalpha treatment specifically increases the risk of certain adverse events in elderly RA patients. This review discusses the currently available evidence relating to the efficacy and safety of anti-TNFalpha medication in RA patients aged >or=65 years treated in clinical trials and observational studies. Despite a slightly less robust effect in elderly patients, anti-TNFalpha treatment has a similar long-term efficacy in patients aged >or=65 years and patients aged <65 years. The majority of the study results showed that anti-TNFalpha treatment does not elevate the risk of infections beyond the risk found in age-matched controls. When a moderate increase in risk was found, this occurred equally in elderly and younger patients. Furthermore, whereas anti-TNFalpha agents were found to be relatively safe in the treatment of elderly RA patients, treatment with corticosteroids significantly elevated the risk of serious infections. Corticosteroids are frequently used in elderly patients, but the evidence suggests that preference should increasingly be given to anti-TNFalpha agents, for which the expected benefits will mostly outweigh the modestly increased risks of associated adverse events.
Radovits
Beáta J
BJ
Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
Kievit
Wietske
W
Laan
Roland F J M
RF
D000368:Aged; D000375:Aging / Q000276:immunology; D000818:Animals; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000628:therapy; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha
Br J Rheumatol. 1998 Apr;37(4):459-60
9619900
Autoimmun Rev. 2009 Jan;8(3):266-73
19022409
Endocr J. 1999 Oct;46(5):643-9
10670749
Circulation. 2003 Jul 1;107(25):3133-40
12796126
Lancet. 2004 Feb 28;363(9410):675-81
15001324
Ann Rheum Dis. 2007 Oct;66(10):1339-44
17261532
Arthritis Rheum. 2007 May;56(5):1433-9
17469100
Arthritis Res Ther. 2003;5(6):290-302
14680505
Autoimmun Rev. 2005 Mar;4(3):153-61
15823501
Ann Rheum Dis. 2005 Oct;64(10):1414-20
15843454
N Engl J Med. 2000 Nov 30;343(22):1586-93
11096165
Arthritis Rheum. 2007 Sep;56(9):2896-904
17763441
Rheumatology (Oxford). 2000 Mar;39(3):321-7
10788543
Ann Rheum Dis. 2008 Aug;67(8):1104-10
17666447
Reumatismo. 2008 Jan-Mar;60(1):41-9
18432324
Aging (Milano). 1996 Aug;8(4):277-81
8904958
Am J Epidemiol. 1980 Jan;111(1):87-98
7352462
N Engl J Med. 1999 Jan 28;340(4):253-9
9920948
Clin Infect Dis. 2004 Aug 1;39(3):295-9
15306993
Drugs Aging. 2006;23(2):167-78
16536638
Mech Ageing Dev. 1999 Feb 1;107(1):1-14
10197784
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
Arthritis Rheum. 2003 Apr;48(4):917-26
12687533
Ann Rheum Dis. 2005 Nov;64 Suppl 4:iv42-3
16239385
Ann Rheum Dis. 2007 Nov;66(11):1473-8
17426065
J Rheumatol. 2005 Jul;32(7):1213-8
15996054
Rheum Dis Clin North Am. 2000 Aug;26(3):455-73
10989507
J Immunol. 2001 Sep 15;167(6):3231-8
11544310
Rheumatology (Oxford). 2005 Dec;44(12):1546-8
16263785
Arthritis Rheum. 2004 Apr;50(4):1051-65
15077287
Rheumatol Int. 2001 Apr;20(3):85-7
11354562
Arthritis Rheum. 2004 May;50(5):1400-11
15146409
J Rheumatol. 2003 Mar;30(3):443-8
12610798
Ann Rheum Dis. 2004 Nov;63 Suppl 2:ii13-ii17
15479864
Arthritis Rheum. 2006 Aug;54(8):2368-76
16868999
Arthritis Rheum. 2002 Jun;46(6):1443-50
12115173
Best Pract Res Clin Rheumatol. 2002 Dec;16(5):707-22
12473269
Ann Intern Med. 1999 Mar 16;130(6):478-86
10075615
N Engl J Med. 1997 Jul 17;337(3):141-7
9219699
Rheumatol Int. 2003 Mar;23(2):70-4
12634939
Am J Physiol. 1992 Feb;262(2 Pt 2):R211-5
1539727
Ann N Y Acad Sci. 2006 Jun;1069:420-7
16855169
Ann Rheum Dis. 2004 Nov;63(11):1372-8
15020312
JAMA. 2006 May 17;295(19):2275-85
16705109
Arthritis Rheum. 2007 Sep;56(9):2905-12
17763428
Am Heart J. 2008 Aug;156(2):336-41
18657665
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S93-9
16273792
Arthritis Rheum. 2007 Jun;56(6):1754-64
17530704
Clin Exp Rheumatol. 1996 Sep-Oct;14(5):537-42
8913656
Aging Cell. 2008 Dec;7(6):805-12
18782346
Arthritis Rheum. 2008 Mar;58(3):667-77
18311816
Rheumatology (Oxford). 2005 Mar;44(3):271-3
15561736
Ann Rheum Dis. 2006 Sep;65(9):1226-9
16414968
Drugs Aging. 2007;24(3):239-54
17362051
Arthritis Rheum. 2002 Sep;46(9):2294-300
12355476
Adv Immunol. 1980;29:287-330
6998260
Arthritis Rheum. 2007 May 15;57(4):679-85
17471545
Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):19-22
15852250
J Rheumatol. 2006 Feb;33(2):234-43
16465653
Ann Rheum Dis. 2005 Oct;64(10):1421-6
15829572
Ann Rheum Dis. 2009 Jul;68(7):1136-45
18753157
Br J Rheumatol. 1986 Nov;25(4):333-41
2946352
Ann Rheum Dis. 2006 Mar;65(3):379-84
16150792
Scand J Immunol. 2004 Jul-Aug;60(1-2):199-208
15238090
Mech Ageing Dev. 1998 May 15;102(2-3):199-209
9720652
Arthritis Rheum. 2004 Jun;50(6):1740-51
15188349
Rheumatology (Oxford). 2007 Jul;46(7):1157-60
17478469
J Immunol. 1993 Jun 15;150(12):5219-30
8515056
Arthritis Rheum. 2004 Nov;50(11):3432-43
15529377
Ann Rheum Dis. 2006 Nov;65(11):1438-43
16644782
Arthritis Res Ther. 2004;6 Suppl 2:S3-S11
15228615
Rheumatology (Oxford). 2005 May;44(5):695-6
15705631
Ageing Res Rev. 2009 Jan;8(1):18-30
18692159
Ann Epidemiol. 1996 Sep;6(5):376-80
8915467
J Rheumatol. 2003 Dec;30(12):2563-71
14719195
Rheumatology (Oxford). 2005 Jun;44(6):714-20
15741198
Arthritis Rheum. 2006 Nov;54(11):3399-407
17075823
Immunity. 2006 May;24(5):495-9
16713964
Exp Gerontol. 2003 Aug;38(8):833-41
12915205
Ann Rheum Dis. 2009 Sep;68(9):1470-3
19015210
Arthritis Rheum. 2007 Apr;56(4):1125-33
17393394
Am J Med. 2004 Mar 1;116(5):305-11
14984815
Ann Rheum Dis. 2009 May;68(5):648-53
18467516
J Rheumatol. 2003 Apr;30(4):691-6
12672185
Gerontology. 2009;55(3):250-8
18849599
Rheumatology (Oxford). 2006 Dec;45(12):1555-7
16690762